弘则医药：高值耗材反内卷 20250812 我们在欧洲市场上的冠脉通路类产品非常全面，包括造影三件套、导管、导丝、 各种球囊等日常 PCI（经皮冠状动脉介入治疗）所需的所有基本和复杂产品。 这些产品都已获得 CE 认证，并且已经销售多年，销量也逐渐增长。 欧洲冠脉通路类耗材市场格局如何？ 摘要 惠泰在欧洲市场冠脉通路类产品线全面，已获 CE 认证并销售多年，销 量稳步增长，覆盖造影三件套、导管、导丝、球囊等 PCI 所需产品。 欧洲冠脉通路耗材市场主要由美敦力和雅培主导，泰尔茂在鞘、亲水导 丝和球囊方面具有较高知名度，中国企业如汇泰和博迈在特定细分领域 崭露头角。 惠泰通过差异化设计如延伸导管和微导管，打破中国品牌同质化印象， 提升品牌形象，并逐步优化其他产品以扩大市场份额，预计未来增长率 可达 40%-50%。 惠泰在欧洲市场主要通过分销模式销售，每个国家有多个经销商负责不 同区域和领域，随着市场打开，将细化到每个地区一个代理商。 惠泰在欧洲使用 APP Medical 自有品牌，延伸导管销量可排名前四，但 球囊等日常使用设备因竞争激烈，难以进入前五。 欧洲市场通路类产品出厂价与国内集采价大致相当，价格浮动 ...

Core Viewpoint - The company reported a significant increase in revenue and a substantial reduction in losses, indicating improved operational efficiency and market positioning in the neuro-interventional medical device sector [1][2]. Financial Performance - The company achieved revenue of RMB 278 million for the fiscal year ending December 31, 2024, representing a year-on-year increase of 19.6% [1]. - Research and development costs amounted to RMB 58.94 million, a decrease of 52.4% compared to the previous year [1]. - The loss attributable to the parent company was RMB 13.62 million, a reduction of 85.51% year-on-year, with a loss per share of RMB 0.36 [1]. - The pre-tax loss narrowed significantly to RMB 12 million, down 88.3% year-on-year, despite a decline in gross margin due to bulk procurement pricing and market competition [1]. Operational Efficiency - The company successfully reduced the expense ratio for sales, distribution, and administrative expenses to 49.6%, down from 66.2% in 2023, reflecting effective cost control and efficiency measures [1]. - The sales volume of acute ischemic stroke treatment devices increased by 45.5%, while revenues from hemorrhagic stroke treatment devices and other interventional devices grew by 104.2% and 109.4%, respectively [1]. Product Development and Market Expansion - The company is focused on upgrading its neuro-interventional business and differentiating its treatment devices to adapt to rapidly changing market conditions [1]. - Research and development efforts are directed towards diverse neuro-interventional treatment devices, with plans to launch at least two major devices in the next 24 months, including self-expanding drug-eluting stents and carotid stents [2]. - The company has received NMPA approval for its intracranial aneurysm embolization assist stent and flow diversion device, which have begun sales [2]. - The company has obtained CE or FDA certifications for several products in overseas markets and is currently conducting over 40 product registrations in 10 countries or regions to expand sales channels [2].